about
Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituentsPyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A proteaseOptimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidateImidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding modeImidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorsThe discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosingProtein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinaseOptimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor DoPotent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation.Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα).Compound Passport Service: supporting corporate collection owners in open innovation.Progress towards a public chemogenomic set for protein kinases and a call for contributions.Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins.Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.The design of potent, non-peptidic inhibitors of hepatitis C protease.Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.Applications of the amino-Cope rearrangement: synthesis of tetrahydropyran, delta-lactone and piperidine targets.Design and campaign synthesis of pyridine-based histone deacetylase inhibitors.Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface.The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilotSolid-phase synthesis of a range of O-phosphorylated peptides by post-assembly phosphitylation and oxidationSolid-phase synthesis of O-mannosylated peptides: two strategies comparedShort and versatile route to a key intermediate for lactacystin synthesisPyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A proteaseSmall-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer
P50
Q27640095-47061C6B-AE0E-4249-9DBF-391EFCEAAB9BQ27642585-5080E25D-C9C3-4A60-B917-63DFBF72ED2DQ27643711-B4981104-AD05-4EC5-AA87-14717B8DF8BEQ27651119-5C3041BC-72BB-400E-AE83-F0C4D7E5FD21Q27652282-2C5CE12A-E6BF-47AB-9DE5-D62FA6A7C502Q27652825-DFF4D7F8-7639-4424-9C6E-FB48C120E142Q27679217-AF653283-839D-4DE7-BF7D-12262B5B140DQ27702205-D6FE5B05-A1AA-4ABC-BFAA-C47C37BD5B9BQ35074916-F532AE81-FA26-4690-9F53-DDC68EECFFF1Q35667799-7D6D5DF7-B5C8-4451-A166-088C8636B885Q38542010-73ABAA2B-E79D-41DB-B2E1-F227023F89F7Q38646648-5B7A5317-4D32-4575-9BB4-E40C8AAB90E5Q38676025-3C08AE22-3FD9-4863-B0CA-B8120643CB05Q38722339-BB89A122-3740-45D3-8A62-10BCB0B85A89Q39920958-3072FC1D-BC02-4601-B050-0B3ADCF3AFB2Q39996694-5479F52F-D44E-4658-B12D-46A24B018113Q40685748-6E9D120A-EFB6-4CB9-9692-8DDE3E16B912Q43040844-14B8348A-B66F-42D4-AD7D-1C24B85D589CQ43048589-A8B37928-2D65-40FB-8589-E15EA7C6A4EFQ44428539-62F85FA1-0F81-45BB-9DDB-FB9FB1556764Q45282999-74624B06-5120-4979-B033-E225E598BC04Q46672664-5779C8E6-3138-46E4-9541-35C1C9BFD780Q47922900-4E4C5128-C241-462F-ACFC-8A9B5FC3977AQ57381994-D3A5B351-898F-4E36-AB65-5F35080CA7A0Q67875900-5BBDF5C7-6617-4E37-A27D-668DC6F7F465Q70498727-70F118CD-7FDC-449E-BDC3-5E7B384CE7A8Q78852815-17D6EA9F-0BBA-4FD5-B81E-9D810F1BDC30Q79307558-09B98B83-5D04-4C8F-BE56-48B6D98A4FAFQ84586863-0AC981CF-F96D-4E34-A6E5-0C897C31E705
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David M. Andrews
@ast
David M. Andrews
@en
David M. Andrews
@es
David M. Andrews
@nl
David M. Andrews
@sl
type
label
David M. Andrews
@ast
David M. Andrews
@en
David M. Andrews
@es
David M. Andrews
@nl
David M. Andrews
@sl
prefLabel
David M. Andrews
@ast
David M. Andrews
@en
David M. Andrews
@es
David M. Andrews
@nl
David M. Andrews
@sl
P106
P1153
7202676480
P21
P31
P3835
david-andrews12
P496
0000-0002-6716-6270